Health & Science
Eli Lilly's Retatrutide Yields 28% Weight Loss in Trial
Eli Lilly's retatrutide led to 28.3% weight loss in a Phase 3 trial, approaching bariatric surgery results. But high side effect rates raise questions.
—5 min read
Category
2 articles
Eli Lilly's retatrutide led to 28.3% weight loss in a Phase 3 trial, approaching bariatric surgery results. But high side effect rates raise questions.
A new study reveals how the APOE2 longevity gene protects neurons from aging and Alzheimer's by boosting DNA repair and resisting cellular senescence.